CHRS Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -93.63% compared to Coherus BioSciences's net margin of -87.96%. Coherus BioSciences's return on equity of -- beat Fortress Biotech's return on equity of --.

Coherus BioSciences has a consensus price target of $4.68, signalling upside risk potential of 371.97%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 807.3%. Given that Fortress Biotech has higher upside potential than Coherus BioSciences, analysts believe Fortress Biotech is more attractive than Coherus BioSciences.

Coherus BioSciences has a beta of 1.011, which suggesting that the stock is 1.124% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

Coherus BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus BioSciences pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Coherus BioSciences quarterly revenues are $54.1M, which are larger than Fortress Biotech quarterly revenues of $14.6M. Coherus BioSciences's net income of -$50.7M is lower than Fortress Biotech's net income of -$12.9M. Notably, Coherus BioSciences's price-to-earnings ratio is 5.22x while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus BioSciences is 0.44x versus 0.47x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics has a net margin of -93.63% compared to Coherus BioSciences's net margin of -114.12%. Coherus BioSciences's return on equity of -- beat Lineage Cell Therapeutics's return on equity of -27.23%.

Coherus BioSciences has a consensus price target of $4.68, signalling upside risk potential of 371.97%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 733.33%. Given that Lineage Cell Therapeutics has higher upside potential than Coherus BioSciences, analysts believe Lineage Cell Therapeutics is more attractive than Coherus BioSciences.

Coherus BioSciences has a beta of 1.011, which suggesting that the stock is 1.124% more volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.414, suggesting its more volatile than the S&P 500 by 41.436%.

Coherus BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus BioSciences pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

Coherus BioSciences quarterly revenues are $54.1M, which are larger than Lineage Cell Therapeutics quarterly revenues of $2.9M. Coherus BioSciences's net income of -$50.7M is lower than Lineage Cell Therapeutics's net income of -$3.3M. Notably, Coherus BioSciences's price-to-earnings ratio is 5.22x while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus BioSciences is 0.44x versus 9.91x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -93.63% compared to Coherus BioSciences's net margin of -2.16%. Coherus BioSciences's return on equity of -- beat Myomo's return on equity of -48.64%.

Coherus BioSciences has a consensus price target of $4.68, signalling upside risk potential of 371.97%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 169.35%. Given that Coherus BioSciences has higher upside potential than Myomo, analysts believe Coherus BioSciences is more attractive than Myomo.

Coherus BioSciences has a beta of 1.011, which suggesting that the stock is 1.124% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Coherus BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus BioSciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Coherus BioSciences quarterly revenues are $54.1M, which are larger than Myomo quarterly revenues of $12.1M. Coherus BioSciences's net income of -$50.7M is lower than Myomo's net income of -$260.1K. Notably, Coherus BioSciences's price-to-earnings ratio is 5.22x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus BioSciences is 0.44x versus 3.90x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -93.63% compared to Coherus BioSciences's net margin of 21.63%. Coherus BioSciences's return on equity of -- beat Pfizer's return on equity of 8.72%.

Coherus BioSciences has a consensus price target of $4.68, signalling upside risk potential of 371.97%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 27.33%. Given that Coherus BioSciences has higher upside potential than Pfizer, analysts believe Coherus BioSciences is more attractive than Pfizer.

Coherus BioSciences has a beta of 1.011, which suggesting that the stock is 1.124% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Coherus BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Coherus BioSciences pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Coherus BioSciences quarterly revenues are $54.1M, which are smaller than Pfizer quarterly revenues of $13.7B. Coherus BioSciences's net income of -$50.7M is lower than Pfizer's net income of $3B. Notably, Coherus BioSciences's price-to-earnings ratio is 5.22x while Pfizer's PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus BioSciences is 0.44x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.